), Higher clinical and microbiological success for Zyvox Versus Vancomycin in MRSA Nosocomial pneumoniaResults of a new international phase 4 study of patients with nosocomial pneumonia proven by culture-proven methicillin-resistant Staphylococcus aureus that the antibiotic linezolid , a statistically significantly higher clinical success rate compared with vancomycin achieved for the primary endpoint. The Zephyr was study, the largest ever conducted in this population. These results are at the 48th Annual Meeting of the Infectious Diseases Society of America presented in Vancouver.

The 2007 Annual Report of the European Antimicrobial Resistance Surveillance System describes the effectiveness of antibiotics in Europe from 1999 to 2006 the report. Noted high prevalence of MRSA in most European countries, varying with large multi-country and inter – center variations. The proportion of S. Aureus infections by MRSA from 0 percent in northern Europe reported 50 percent in Southern Europe, and 60 percent in some intensive care units ()).2 Nosocomial pneumonia caused by resistant pathogens such as MRSA, the potential a serious and life-threatening infection has become the 4th.Besides the Isabel system is started the Emperor. ‘Pilot assays ‘to the emergency medical aid Risk Initiative, an Internet-based diagnostic tool for emergency department Doctors & Dentists The tool requires physicians and nurses to make a series of questions to certain tests and note their activities on a chart for patients with high-risk symptoms point. Doug Bonacum , vice president of safety management on Emperor, said: ‘There are so many things that may go wrong for trying to obtain patient for an check, follow-up following treatment, J a further system approach ‘Stephen Horowitz , a specialist in Paediatric gastroenterology at the University of Virginia in pediatric clinic, said:’.